[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Gross ME, Shazer RL, Agus DB (2004) Targeting the HER-kinase axis in cancer. Semin Oncol 31:9–20

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423

Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 353:1673–1684

Nahta R, Yu D, Hung MC et al (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280

Burris HA III, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405

Mack L, Kerkvliet N, Doig G et al (1997) Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol 28:974–979

Rosenthal SI, Depowski PL, Sheehan CE et al (2002) Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Applied immunohistochemistry & molecular morphology. Appl Immunohistochem Mol Morph 10:40–46

Barron JJ, Cziraky MJ, Weisman T et al (2009) HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist 14:760–768

Pedrini JL, Francalacci Savaris R, Casales Schorr M et al (2011) The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer. Tumori 97:704–710

Solomayer EF, Becker S, Pergola-Becker G et al (2006) Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Canc Res Treat 98:179–184

Wulfing P, Borchard J, Buerger H et al (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12:1715–1720

Dijkers EC, de Vries EG, Kosterink JG et al (2008) Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. Curr Pharmacol Des 14:3348–3362

Lower EE, Glass E, Blau R et al (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301–306

Carlson RW, Allred DC, Anderson BO National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf

Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK et al (2003) Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 127:1451–1457

Capala J, Bouchelouche K (2010) Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy. Curr Opin Oncol 22:559–566

Dijkers EC, Oude Munnink TH, Kosterink JG et al (2010) Biodistribution of [89Zr]-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Therap 87:586–592

Kurihara H, Hamada A, Yoshida M et al (2015) [64Cu]-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. Eur J Nucl Med Mol Imaging Res 5:8

Mortimer JE, Bading JR, Colcher DM et al (2014) Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using [64Cu]-DOTA-trastuzumab PET. J Nucl Med 55:23–29

Gaykema SB, Schroder CP, Vitfell-Rasmussen J et al (2014) [89Zr]-trastuzumab and [89Zr]-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res 20:3945–3954

Beylergil V, Morris PG, Smith-Jones PM et al (2013) Pilot study of [68Ga]-DOTA-F(ab′)2-trastuzumab in patients with breast cancer. Nucl Med Commun 34:1157–1165

Baum RP, Prasad V, Muller D et al (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 51:892–897

Gebhart G, Lamberts LE, Wimana Z et al (2015) Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. Ann Oncol. doi: 10.1093/annonc/mdv577

Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013

Vosjan MJ, Perk LR, Visser GW et al (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 5:739–743

Wooten AL, Madrid E, Schweitzer GD et al (2013) Routine production of Zr-89 using an automated module. Appl Sci 3:593–613

Holland JP, Sheh Y, Lewis JS (2009) Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36:729–739

Lindmo T, Boven E, Cuttitta F et al (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77–89

Lemmens HJ, Bernstein DP, Brodsky JB (2006) Estimating blood volume in obese and morbidly obese patients. Obes Surg 16:773–776

Vance GH, Barry TS, Bloom KJ et al (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133:611–612

Lewis JT, Ketterling RP, Halling KC et al (2005) Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 124:273–281

Brunelli M, Manfrin E, Martignoni G et al (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria. Am J Clin Pathol 131:678–682

Boyer AP, Collier TS, Vidavsky I et al (2013) Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Mol Cell Prot 12:180–193

Arribas J, Baselga J, Pedersen K et al (2011) p95HER2 and breast cancer. Cancer Res 71:1515–1519

Price-Schiavi SA, Jepson S, Li P et al (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Intl J Cancer 99:783–791

Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402

Zhang S, Huang WC, Li P et al (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Med 17:461–469